TradingFloor AI · Stock Terminal

UTHR - Ticker AI Digest

United Therapeutics Corporation 📰 1
515.46000000 | Today -2.36% ●
Desk Snapshot GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
United Therapeutics Corporation in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, Today’s AI, and the deeper desks.
UTHR Data 2026-08-31 Preview Mode
Core Deck
Deep Dive Modules
Home

Digested News

Today's Catalysts (UTHR) 1
UTHR 15:22
United Therapeutics Corporation
LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
AI 0
No items for this category on selected date.
Acquisitions 1
UTHR 10:15
United Therapeutics Corporation
United Therapeutics Expands Regenerative Medicine Portfolio With Thymmune Acquisition
Admission 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 1
UTHR 09:30
United Therapeutics Corporation
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
BlockListing 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Circular 0
No items for this category on selected date.
ClinicalTrial 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
DirectorateChange 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Dividend 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Form83 0
No items for this category on selected date.
GeneralMeeting 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
IssueOfEquity 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
MonthlyFactsheet 0
No items for this category on selected date.
NAV 0
No items for this category on selected date.
NameChange 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
OwnShares 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
ProfitWarning 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Prospectus 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 0
No items for this category on selected date.
SchemeOfArrangement 0
No items for this category on selected date.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
TVR 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
US News 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 24
UTHR 15:22
United Therapeutics Corporation
LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
UTHR 19:42
United Therapeutics Corporation
Q1 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
UTHR 11:55
United Therapeutics Corporation
UTHR Strengthens Regenerative Medicine Platform With Thymmune Deal
UTHR 17:13
United Therapeutics Corporation
Can Yutrepia Maintain Momentum for LQDA Stock in 2026?
UTHR 10:15
United Therapeutics Corporation
United Therapeutics Expands Regenerative Medicine Portfolio With Thymmune Acquisition
UTHR 09:41
United Therapeutics Corporation
United Therapeutics buys Thymmune Therapeutics
UTHR 09:30
United Therapeutics Corporation
United Therapeutics Corporation Acquires Thymmune Therapeutics
UTHR 12:37
United Therapeutics Corporation
The Oliver Patch Project Announces United Therapeutics Corporation Named Visionary/Presenting Sponsor of National Patch Day 2026
UTHR 15:11
United Therapeutics Corporation
Therapeutics Stocks Q1 Recap: Benchmarking Vertex Pharmaceuticals (NASDAQ:VRTX)
UTHR 14:47
United Therapeutics Corporation
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
UTHR 03:46
United Therapeutics Corporation
Big Pharma Has a Case of Merger Mania
UTHR 18:35
United Therapeutics Corporation
Is MannKind Corporation (MNKD) A Good Stock To Buy Now?
UTHR 09:30
United Therapeutics Corporation
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
UTHR 07:00
United Therapeutics Corporation
Bull of the Day: Neurocrine Biosciences (NBIX)
UTHR 07:00
United Therapeutics Corporation
Bull of the Day: Neurocrine Biosciences (NBIX)
UTHR 14:37
United Therapeutics Corporation
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest
UTHR 17:24
United Therapeutics Corporation
Therapeutics Stocks Q1 Recap: Benchmarking Biogen (NASDAQ:BIIB)
UTHR 17:43
United Therapeutics Corporation
Q1 Earnings Outperformers: United Therapeutics (NASDAQ:UTHR) And The Rest Of The Therapeutics Stocks
UTHR 01:48
United Therapeutics Corporation
Market-Weighted Healthcare or Active Manager Selection? IYH vs. PINK
UTHR 01:48
United Therapeutics Corporation
Market-Weighted Healthcare or Active Manager Selection? IYH vs. PINK
UTHR 09:20
United Therapeutics Corporation
Should Invesco S&P MidCap Quality ETF (XMHQ) Be on Your Investing Radar?
UTHR 17:37
United Therapeutics Corporation
iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns
UTHR 09:20
United Therapeutics Corporation
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
UTHR 12:35
United Therapeutics Corporation
These 3 Stocks Lowered Their Share Counts Drastically in Q1

Today's AI

UTHR · Agentic Market Intelligence

UTHR intelligence is listening.

The engine is monitoring news, price structure, forecasts and financial changes. New scored evidence will appear here against this stock automatically.

Live catalyst scoringAI price pathsRisk-aware triggersFinancial blend
AI bias0.0
Bullish0
Bearish0
Today's AI Starts With News

1 live catalyst is opening Today’s AI for UTHR.

Start with the live headline tape first. Today’s AI findings sit next, and the AI Blend stack drops lower once the news context is framed. Financial Forecastist now feeds the blend too.
Live Tape Data 2026-08-31 Blend Lower Down
Read the alert tape first, then open Today’s AI findings. Use AI Expand on any card to open the AI explanation, results tables and financial forecast rows instantly.
1 Today
Front Of Desk
United Therapeutics Corporation has fresh news flow live now, so Today’s AI is leading with the tape before the blended signal stack below.
15:22 Today's Catalyst LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
Single-Ticker Today's AI
UTHR signal theatre built from scored market catalysts, automated AI forecasts, financial forecasting and live trigger logic.

This is the ticker-specific Today’s AI desk for United Therapeutics Corporation. It compresses the live catalyst tape, bullish and bearish scoring, AI price forecasts, financial forecasting and trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI + Financial Blend Buy / Sell Trigger Engine Today's AI Findings
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full UTHR Today’s AI cockpit.

Subscription turns this tab into a live signal desk with today’s news findings at the top, AI plus financial blend comparisons at the bottom, buy and sell trigger logic, and the full findings ledger behind every scored row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific Today’s AI stack, sentiment gauges, AI blend stage, and the full findings ledger for UTHR on 2026-08-31.

Fundamentals Matrix

About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

🌐 Visit Official Website ↗

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
23.6B
Enterprise Value
20.5B
Public Float
91.7
Broker Target
665.2308
Shares Out
42.4M
Long Interest
100
Short Interest
0
Exchange
NASDAQ
Currency Code
USD
ISIN
US91307C1027
Ex-Dividend
-
Yield
0.00%
Dividend Rate
-
EPS
27.02
Market
NASDAQ
Standard Lists
Not currently ranked
Sector
Pharmaceuticals and BiotechnologyUS fundamentals
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

1 live alert now opens the financials desk for UTHR.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-08-31 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
1 Alerts
Front Of Desk
United Therapeutics Corporation has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
15:22 Today's Alert LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
-
Earnings Date
-
Net Debt
-1.6B
Cash
1.6B
EPS
27.02
Net Income
1.3B
Revenue
3.2B
Enterprise Value
20.5B
Trailing PE
20.574
Forward PE
20.202
Price Sales TTM
7.4442
Price Book MRQ
4.0001
EV Revenue
6.4622
EV EBITDA
11.9543
Financial Forecastist

Mixed financial engine

Revenue is slipping -1.6% against the prior comparable period. Net margin is compressing by 5.4 pts. Net debt is coming down +36.8%.

Revenue -1.6% Net Income -14.7% FCF -6.2% Current Ratio 4.79x Forward Rev 820.8M
Mixed
Quarter Revenue
781.5M
-1.6%
vs prior comparable quarter
Net Margin
+35.2%
-5.4 pts
profitability pulse
Free Cash Flow
362.5M
-6.2%
cash conversion
Net Debt / EBITDA
-3.1x
-36.8%
lower is cleaner
Revenue Engine

Latest quarter printed 781.5M with the top line cooling off against the last comparable period.

Profit Stack

Net income landed at 274.9M and the margin profile is tightening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 1.1B while net debt is -1.1B. The leverage stack is cleaning up.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q3 2025
Consensus
812.9M
Revenue Path
6.96
EPS / Earnings
Growth cue +0.1%
Q1 2026
Consensus
797.4M
Revenue Path
6.86
EPS / Earnings
Growth cue +0.0%
Q2 2026
Consensus
807.7M
Revenue Path
6.86
EPS / Earnings
Growth cue +0.1%
Q3 2026
Consensus
820.8M
Revenue Path
7.03
EPS / Earnings
Growth cue -0.0%
FY 2026
Consensus
3.2B
Revenue Path
27.06
EPS / Earnings
Growth cue -0.0%
FY 2027
Consensus
3.7B
Revenue Path
31.61
EPS / Earnings
Growth cue +0.2%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q1 2026 781.5M 274.9M 362.5M -1.1B
Q4 2025 790.2M 364.3M 173.3M -1.6B
Q3 2025 799.5M 338.7M 351.6M -1.1B
Q2 2025 798.6M 309.5M 129.5M -1.6B
Q1 2025 794.4M 322.2M 386.3M -1.7B
Q4 2024 735.9M 301.3M 254.5M -1.4B

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 3.2B 1.3B 1.8B 1.0B
FY 2024 2.9B 1.2B 1.7B 1.1B
FY 2023 2.3B 984.8M 1.4B 747.6M
FY 2022 1.9B 727.3M 1.0B 663.7M
FY 2021 1.7B 475.8M 736.8M 477.4M

Structure DNA

Market Structure DNA

Balanced Structure profile with trend mixed

Price is 81.6% through the 52-week range, -2.2% vs 50DMA and +8.6% vs 200DMA. 100.0% of the register is locked by institutions and insiders, leaving 0.0% free float. Capital rhythm reads no cadence with forward yield near 0.0% and payout around 0.0%.

Trend mixed Institutional gravity Moderate income rhythm As Of 2026-07-07
Balanced Structure
Structure Score
61.2 / 100
Balanced Structure
Trend Stack
-2.2% / +8.6%
vs 50DMA / 200DMA
52W Position
81.6%
auction position inside the yearly range
Ownership Lock
100.0%
102.0% institutions | 2.0% insiders
Pressure Pocket
5.7% short float
Short ratio 4.5x | monthly -6.3%
Capital Rhythm
No cadence
Yield 0.0% | payout 0.0%
Trend Runway

Implied spot is 547.25 with the stock -2.2% vs 50DMA and +8.6% vs 200DMA. The tape is sitting 81.6% through the 52-week range, which frames the regime as trend mixed.

Ownership Register

Institutions hold about 102.0% and insiders about 2.0%, locking roughly 100.0% of the register and leaving 0.0% in free float. That reads as institutional gravity.

Pressure Pocket

Short pressure is running near 5.7% of float with short ratio 4.5x and monthly change -6.3%. That gives us a read on whether the tape is clean, crowded, or coiled.

Capital Rhythm

Dividend cadence reads no cadence with - event(s) in the last full year, a five-year average of -, and stability score 0.0/100. Forward yield sits near 0.0% while payout is around 0.0%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

No cadence
Year Dividend Count Context
Dividend history has not been normalized yet.

Structure Facts

Live Snapshot
Implied Spot
547.25
derived from market cap / shares
52W High
609.35
upper auction edge
52W Low
272.12
lower auction edge
Beta
0.58
volatility character
Shares Out
42.4M
fully diluted count
Shares Float
38.9M
tradable register
Shares Short
2.1M
borrowed stock
Short Ratio
4.5x
days-to-cover style read
Ex-Dividend
-
next ex-date not supplied
Dividend Pay
-
payment date not supplied
Last Split
2:1
2009-09-23

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
92.1259
Institutions As Of
2026-05-31
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
0
Institution Holders Tracked
40
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data · UTHR · Last 30 Days

Short D · 12/26 EMA spread with 9 signal

Red histogram bars show short loading accelerating. Green bars show short covering accelerating. The two lines expose the crossover before the raw holder table does.

Short D waiting

Building UTHR short-momentum read

Short D compares the ticker’s disclosed short-position momentum with its own signal line.

Short D—
Signal—
Momentum—

Declared Short Holders

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for UTHR, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-08-31 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
1 Today
Catalyst Pulse
United Therapeutics Corporation has fresh news flow live now, so the tape is framing the chart workspace below.
15:22 Today's Catalyst LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
AI Charts Studio
UTHR Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-08-31 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
Desk Snapshot Member Login
AI AutoDetection Automatic bull / bear chart read
Detected market structure
Analysing selected range
Why this call
Waiting for sufficient price history.
Invalidation
—
Updates with the timeframe.
Bull caseCalculating upside confirmation.
Bear caseCalculating downside confirmation.
Indicators0
Technicals0
RSI Gauge
Price Change
AI Forecast